S&P 500 caps off strongest week in five years
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Verizon planning new round of layoffs this week - Barron’s
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
AbbVie (ABBV) Announced New Positive Results from Phase 2b Data on Upadacitinib in Atopic Dermatitis
February 20, 2018 5:49 AM ESTAbbVie (NYSE: ABBV) today presented new positive results from a Phase 2b dose-ranging study evaluating upadacitinib, an investigational, once-daily oral JAK1-selective inhibitor, in adult patients with moderate to severe atopic dermatitis. These results were featured during the "Late-Breaking Research: Clinical Trials" session at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego. Upadacitinib is not approved by regulatory authorities and its safety and... More
